| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 4, 2023 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 15,890 | $10.30 | $163,667.00 | -100% | -9.7% | +53.7% | |
| Apr 4, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $225.65 | $3,610,391.13 | -36.2% | -1.5% | +1.8% | |
| Apr 3, 2023 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 3,684 | $82.09 | $302,419.56 | -5.0% | +1.7% | -28.6% | |
| Apr 3, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $350.49 | $73,603,586.59 | - | +31.6% | +117.8% | |
| Apr 3, 2023 | PCRX Pacira Biosciences, Inc. | Brege Laura62 | Director | Sell | 7,000 | $40.72 | $285,040.00 | -40.8% | -3.1% | -31.1% | |
| Apr 3, 2023 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 491 | $37.72 | $18,518.75 | -0.6% | +51.1% | +11.0% | |
| Apr 3, 2023 | BCRX Biocryst Pharmaceuticals Inc | Thackray Helen M.78 | Chief R&D Officer | Sell | 7,000 | $8.29 | $58,030.00 | -3.3% | -15.8% | -44.0% | |
| Mar 31, 2023 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 205,000 | $342.01 | $70,111,869.48 | - | +35.3% | +121.5% | |
| Mar 31, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 8,000 | $221.53 | $1,772,202.34 | -28.0% | -1.9% | +1.9% | |
| Mar 31, 2023 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 15,000 | $0.05 | $675.00 | - | - | - | |
| Mar 30, 2023 | TSNDF Terrascend Corp. | Swartzman Lisa | Director | Sell | 2,423 | $1.51 | $3,658.73 | -1.5% | - | - | |
| Mar 30, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $217.34 | $3,477,360.29 | -39.7% | -1.9% | +4.9% | |
| Mar 29, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Morningside Venture Investments Ltd93 | 10% Owner | Sell | 29,048 | $30.45 | $884,511.60 | -0.4% | -25.3% | -90.3% | |
| Mar 29, 2023 | TSNDF Terrascend Corp. | Jw Asset Management, LLC65 | Executive Chairman | Buy | 10,500 | $1.53 | $16,018.80 | - | - | - | |
| Mar 29, 2023 | TSNDF Terrascend Corp. | Ghanem Ziad | President And COO | Buy | 12,600 | $1.52 | $19,152.00 | +18.4% | - | - | |
| Mar 28, 2023 | TSNDF Terrascend Corp. | Ghanem Ziad | President And COO | Buy | 3,000 | $1.49 | $4,470.00 | +4.6% | - | - | |
| Mar 28, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 8,000 | $219.98 | $1,759,803.41 | -48.4% | +0.8% | +11.1% | |
| Mar 28, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Morningside Venture Investments Ltd93 | 10% Owner | Sell | 160,964 | $30.42 | $4,896,561.00 | -0.7% | -26.5% | -90.6% | |
| Mar 27, 2023 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | CEO | Sell | 44,484 | $80.77 | $3,592,855.91 | -4.9% | +7.5% | -27.0% | |
| Mar 27, 2023 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 14,528 | $81.13 | $1,178,656.64 | -16.6% | +7.5% | -27.0% | |
| Mar 27, 2023 | TSNDF Terrascend Corp. | Ghanem Ziad | President And COO | Buy | 12,500 | $1.40 | $17,500.00 | +23.6% | - | - | |
| Mar 27, 2023 | EOLS Evolus, Inc. | Moatazedi David68 | See Remarks | Sell | 6,110 | $8.47 | $51,751.70 | -1.0% | -12.2% | +64.7% | |
| Mar 27, 2023 | TSNDF Terrascend Corp. | Stauffer Keith | CFO | Buy | 50,000 | $1.44 | $72,000.00 | +384.5% | - | - | |
| Mar 27, 2023 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 46,129 | $10.67 | $492,196.43 | -5.2% | -1.7% | -23.1% | |
| Mar 27, 2023 | TSNDF Terrascend Corp. | Jw Asset Management, LLC65 | Executive Chairman | Buy | 43,150 | $1.43 | $61,842.58 | - | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.